Download PDF
Semin Neurol 2003; 23(3): 253-264
DOI: 10.1055/s-2003-814737
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Practical Consultations: Multiple Sclerosis

Dean M. Wingerchuk1 , Jonathan L. Carter2
  • 1Assistant Professor of Neurology, Multiple Sclerosis Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona
  • 2Associate Professor of Neurology, Multiple Sclerosis Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona
Further Information

Publication History

Publication Date:
14 January 2004 (online)

    Permissions and Reprints

ABSTRACT

People with multiple sclerosis (MS) are increasingly referred for specialty care to tertiary centers, particularly for advice regarding initiation and monitoring of immunomodulatory therapies. However, the generalist must still be able to apply appropriate skills and technology to diagnose the disease and its complications, provide basic counseling of patients, and be aware of potential treatment options at the time of diagnosis and when therapeutic regimens fail. A general approach, supported by evidence where possible, to common and contemporary clinical issues in MS care is provided in a case-based narrative.

KEYWORDS

Multiple sclerosis - clinically isolated syndrome - immunomodulating therapies

REFERENCES

  • 1 Morrissey S P, Miller D H, Kendall B E. et al . The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study.  Brain . 1993;  116 135-146
    PubMedGoogle Scholar
  • 2 O'Riordan J I, Thompson A J, Kingsley D P. et al . The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up.  Brain . 1998;  121 495-503
    CrossrefPubMedGoogle Scholar
  • 3 Brex P A, Ciccarelli O, O'Riordan J I, Sailer M, Thompson A J, Miller D H. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.  N Engl J Med . 2002;  346 158-164
    CrossrefPubMedGoogle Scholar
  • 4 Poser C M, Paty D W, Scheinberg L C. et al . New diagnostic criteria for multiple sclerosis: guidelines for research protocols.  Ann Neurol . 1983;  13 227-231
    CrossrefPubMedGoogle Scholar
  • 5 McDonald W I, Compston A, Edan G. et al . Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis.  Ann Neurol . 2001;  50 121-127
    CrossrefPubMedGoogle Scholar
  • 6 Barkhof F, Filippi M, Miller D H. et al . Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite multiple sclerosis.  Brain . 1997;  120 2059-2069
    CrossrefPubMedGoogle Scholar
  • 7 Tintoré M, Rovira A, Martinez M. et al . Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis.  AJNR . 2000;  21 702-706
    PubMedGoogle Scholar
  • 8 Dalton C M, Brex P A, Miszkiel K A. et al . Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis.  Ann Neurol . 2002;  52 47-53
    CrossrefPubMedGoogle Scholar
  • 9 Tintoré M, Rovira A, Rio J. et al . New diagnostic criteria for multiple sclerosis: application in first demyelinating episode.  Neurology . 2003;  60 27-30
    CrossrefPubMedGoogle Scholar
  • 10 Brex P A, Miszkiel K A, O'Riordan J I. et al . Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow-up MRI.  J Neurol Neurosurg Psychiatry . 2001;  70 390-393
    CrossrefPubMedGoogle Scholar
  • 11 Berger T, Rubner P, Schautzer F. et al . Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.  N Engl J Med . 2003;  349 139-145
    CrossrefPubMedGoogle Scholar
  • 12 Noseworthy J N, Lucchinetti C F, Rodriguez M, Weinshenker B G. Multiple sclerosis.  N Engl J Med . 2000;  343 938-952
    CrossrefPubMedGoogle Scholar
  • 13 Thompson A J, Montalban X, Barkhof F. et al . Diagnostic criteria for primary progressive multiple sclerosis: a position paper.  Ann Neurol . 2000;  47 831-835
    CrossrefPubMedGoogle Scholar
  • 14 Jacobs L D, Beck R W, Simon J H. et al . Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.  N Engl J Med . 2000;  343 898-904
    CrossrefPubMedGoogle Scholar
  • 15 Comi G, Filippi M, Barkhof F. et al . Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.  Lancet . 2001;  357 1576-1582
    CrossrefPubMedGoogle Scholar
  • 16 O'Connor P. Key issues in the diagnosis and treatment of multiple sclerosis.  Neurology . 2002;  59(Sl3) S1-S33
    PubMedGoogle Scholar
  • 17 Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis.  N Engl J Med . 2000;  343 1430-1438
    CrossrefPubMedGoogle Scholar
  • 18 The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.  Neurology . 1993;  43 655-661
    PubMedGoogle Scholar
  • 19 Johnson K, Brooks B, Cohen J. et al . Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial.  Neurology . 1995;  45 1268-1276
    CrossrefPubMedGoogle Scholar
  • 20 Jacobs L D, Cookfair D L, Rudick R A. et al . Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis.  Ann Neurol . 1996;  39 285-294
    CrossrefPubMedGoogle Scholar
  • 21 PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis.  Lancet . 1998;  352 1498-1504
    CrossrefPubMedGoogle Scholar
  • 22 Comi G, Filippi M, Wolinsky J, and the European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis.  Ann Neurol . 2001;  49 290-297
    CrossrefPubMedGoogle Scholar
  • 23 Stone L A, Frank J A, Albert P S. et al . The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis.  Ann Neurol . 1995;  37 611-619
    CrossrefPubMedGoogle Scholar
  • 24 Li D KB, Paty D W. and the UBC MS/MRI Analysis Research Group and PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis.  Ann Neurol . 1999;  46 197-206
    CrossrefPubMedGoogle Scholar
  • 25 IFNB Multiple Sclerosis Study Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years.  Neurology . 1996;  47 889-894
    PubMedGoogle Scholar
  • 26 PRISMS Study Group. PRISMS-4: long-term efficacy of interferon beta-1a in relapsing MS.  Neurology . 2001;  56 1628-1636
    PubMedGoogle Scholar
  • 27 Rice G. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.  Arch Neurol . 2001;  58 1297-1298
    PubMedGoogle Scholar
  • 28 Paty D W, Goodkin D, Thompson A, Rice G. Guidelines for physicians with patients on IFNβ-1: the use of an assay for neutralizing antibody.  Neurology . 1996;  47 865-866
    PubMedGoogle Scholar
  • 29 Panitch H, Goodin D S, Francis G. for the EVIDENCE Study Group and the University of British Columbia MS/MRI Research Group et al Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial.  Neurology . 2002;  59 1496-1506
    CrossrefPubMedGoogle Scholar
  • 30 Durelli L, Verdun E, Barbero P. et al . Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).  Lancet . 2002;  359 1453-1460
    CrossrefPubMedGoogle Scholar
  • 31 Clanet M, Radue E W, Kappos L. et al . A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS.  Neurology . 2002;  59 1507-1517
    CrossrefPubMedGoogle Scholar
  • 32 Khan O A, Dhib-Jalbut S S. Neutralizing antibodies to interferon β-1a and interferon β-1b in MS patients are cross-reactive.  Neurology . 1998;  51 1698-1702
    PubMedGoogle Scholar
  • 33 Markovic-Plese S, Bielekova B, Kadom N. et al . Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon β-1b.  Neurology . 2003;  60 1849-1851
    PubMedGoogle Scholar
  • 34 Gobbini M I, Smith M E, Richert N D, Frank J A, McFarland H F. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis.  J Neuroimmunol . 1999;  99 142-149
    CrossrefPubMedGoogle Scholar
  • 35 Patti F, Cataldi M L, Nicoletti F, Reggio E, Nicoletti A, Reggio A. Combination of cyclophosphamide and interferon-β halts progression in patients with rapidly transitional multiple sclerosis.  J Neurol Neurosurg Psychiatry . 2001;  71 404-407
    CrossrefPubMedGoogle Scholar
  • 36 Lublin F, Baier M, Cutter G. et al . Results of the extension of a trial to assess the longer term safety of combining interferon beta-1a and glatiramer acetate.  Neurology . 2002;  58 (suppl 3) A85
    PubMedGoogle Scholar
  • 37 Herndon R M. Why secondary progressive multiple sclerosis is a relentlessly progressive disease.  Arch Neurol . 2002;  59 301-304
    CrossrefPubMedGoogle Scholar
  • 38 European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis.  Lancet . 1998;  352 1491-1497
    CrossrefPubMedGoogle Scholar
  • 39 Kappos L, and the European Study Group on Interferon β1b. Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS.  Neurology . 2001;  57 1969-1975
    PubMedGoogle Scholar
  • 40 Goodkin D. and the North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial (abstract).  Neurology . 2000;  54 2352
    PubMedGoogle Scholar
  • 41 Secondary Progressive Efficacy Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS.  Neurology . 2001;  56 1496-1504
    PubMedGoogle Scholar
  • 42 Cohen J A, Cutter G R, Fischer J S, for the IMPACT Investigators. et al . Benefit of interferon β-1a on MSFC progression in secondary progressive MS.  Neurology . 2002;  59 679-687
    CrossrefPubMedGoogle Scholar
  • 43 Bornstein M B, Miller A, Slagle S. et al . A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis.  Neurology . 1991;  41 533-539
    CrossrefPubMedGoogle Scholar
  • 44 Hartung H P, and the Mitoxantrone in Multiple Sclerosis Study Group. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.  Lancet . 2002;  360 2018-2025
    CrossrefPubMedGoogle Scholar
  • 45 Durelli L, Cocito D, Riccio A. et al . High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunological correlations.  Neurology . 1986;  36 238-243
    PubMedGoogle Scholar
  • 46 Milligan N M, Newcombe R, Compston D A. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis. 1. Clinical effects.  J Neurol Neurosurg Psychiatry . 1987;  50 511-516
    PubMedGoogle Scholar
  • 47 Alam S M, Kyriakides T, Lawden P K, Newman P K. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose.  J Neurol Neurosurg Psychiatry . 1993;  56 1219-1220
    PubMedGoogle Scholar
  • 48 Barnes D, Hughes R, Morris R. et al . Randomized trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.  Lancet . 1997;  349 902-906
    CrossrefPubMedGoogle Scholar
  • 49 Millar J HD, Vas C J, Noronha M J. et al . Long-term treatment of multiple sclerosis with corticotropin.  Lancet . 1967;  2 429-431
    PubMedGoogle Scholar
  • 50 Weinshenker B G, O'Brien P, Petterson T. et al . A randomized trial of plasma exchange in acute CNS inflammatory demyelinating disease.  Ann Neurol . 1999;  46 878-886
    CrossrefPubMedGoogle Scholar
  • 51 Keegan M, Pineda A A, McClelland R L. et al . Plasma exchange for severe attacks of CNS demyelination: predictors of response.  Neurology . 2002;  58 143-146
    CrossrefPubMedGoogle Scholar
  • 52 Sibley W A, Bamford C R, Clark K. Clinical viral infections and multiple sclerosis.  Lancet . 1985;  1 1313-1315
    PubMedGoogle Scholar
  • 53 Walther E U, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management.  Neurology . 1999;  53 1622-1627
    CrossrefPubMedGoogle Scholar
  • 54 Confavreux C, Hutchinson M, Hours M M. et al . Rate of pregnancy-related relapse in multiple sclerosis.  N Engl J Med . 1998;  339 285-291
    CrossrefPubMedGoogle Scholar
  • 55 Damek D M, Shuster E A. Pregnancy and multiple sclerosis.  Mayo Clin Proc . 1997;  72 977-989
    PubMedGoogle Scholar
  • 56 Sicotte N L, Liva S M, Klutch R. et al . Treatment of multiple sclerosis with the pregnancy hormone estriol.  Ann Neurol . 2002;  52 421-428
    CrossrefPubMedGoogle Scholar
  • 57 Sadovnick A D, Ebers G C. Genetics of multiple sclerosis.  Neurol Clin . 1995;  13 99-118
    PubMedGoogle Scholar
  • 58 Compston A. Genetic susceptibility to multiple sclerosis. In: Compston A, Ebers GC, Lassman H, et al, eds. McAlpine's Multiple Sclerosis 3rd ed. London: Churchill Livingstone 1998: 101-190
    Google Scholar
  • 59 Ebers G C, Sadovnick A D, Risch N J. A genetic basis for familial aggregation in multiple sclerosis.  Nature . 1995;  377 150-151
    CrossrefPubMedGoogle Scholar
  • 60 Sadovnick A D, Dircks A, Ebers G C. Genetic counseling in multiple sclerosis: risk to sibs and children of affected individuals.  Clin Genet . 1999;  56 118-122
    CrossrefPubMedGoogle Scholar